版本:
中国

BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence

Oct 6 Orexo AB :

* U.S. FDA approves Orexo's low dose zubsolv buprenorphine and naloxone sublingual tablets (CIII)

* Orexo U.S. says U.S. FDA has approved Zubsolv 0.7mg/0.18mg for treatment of patients with opioid dependence Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐